The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Arginase Deficiency Therapeutics Market Research Report 2025
Synopsis
Argininemia, also called arginase deficiency, is an autosomal recessive urea cycle disorder where adeficiency of the enzyme arginase causes a buildup of arginine and ammonia in the blood.
The global Arginase Deficiency Therapeutics market was valued at US$ 102.5 million in 2023 and is anticipated to reach US$ 137 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
The Arginase deficiency drugs market is driven by the growing awareness and diagnosis of this rare genetic disorder. As understanding of the disease improves, more patients are being identified and seeking treatment options. The development of targeted therapies to address the underlying metabolic abnormalities associated with Arginase deficiency has also contributed to market growth. Additionally, government initiatives and orphan drug designations have facilitated research and development in this area. However, the market faces challenges like limited patient populations, high treatment costs, and the need for specialized medical expertise for diagnosis and management. Overcoming these challenges through increased awareness, early diagnosis, and affordable access to therapies will be essential for the sustained growth of the Arginase deficiency drugs market.
This report aims to provide a comprehensive presentation of the global market for Arginase Deficiency Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Arginase Deficiency Therapeutics.
Report Scope
The Arginase Deficiency Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Arginase Deficiency Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Arginase Deficiency Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Helsinn Healthcare
Novartis Pharmaceuticals
Horizon Pharma
Medicis Pharmaceutical
Segment by Type
Oral
Injection
Segment by Application
Hospital
Drugs Stores
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Arginase Deficiency Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Argininemia, also called arginase deficiency, is an autosomal recessive urea cycle disorder where adeficiency of the enzyme arginase causes a buildup of arginine and ammonia in the blood.
The global Arginase Deficiency Therapeutics market was valued at US$ 102.5 million in 2023 and is anticipated to reach US$ 137 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
The Arginase deficiency drugs market is driven by the growing awareness and diagnosis of this rare genetic disorder. As understanding of the disease improves, more patients are being identified and seeking treatment options. The development of targeted therapies to address the underlying metabolic abnormalities associated with Arginase deficiency has also contributed to market growth. Additionally, government initiatives and orphan drug designations have facilitated research and development in this area. However, the market faces challenges like limited patient populations, high treatment costs, and the need for specialized medical expertise for diagnosis and management. Overcoming these challenges through increased awareness, early diagnosis, and affordable access to therapies will be essential for the sustained growth of the Arginase deficiency drugs market.
This report aims to provide a comprehensive presentation of the global market for Arginase Deficiency Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Arginase Deficiency Therapeutics.
Report Scope
The Arginase Deficiency Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Arginase Deficiency Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Arginase Deficiency Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Helsinn Healthcare
Novartis Pharmaceuticals
Horizon Pharma
Medicis Pharmaceutical
Segment by Type
Oral
Injection
Segment by Application
Hospital
Drugs Stores
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Arginase Deficiency Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Arginase Deficiency Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Arginase Deficiency Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Drugs Stores
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Arginase Deficiency Therapeutics Market Perspective (2019-2030)
2.2 Arginase Deficiency Therapeutics Growth Trends by Region
2.2.1 Global Arginase Deficiency Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Arginase Deficiency Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Arginase Deficiency Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Arginase Deficiency Therapeutics Market Dynamics
2.3.1 Arginase Deficiency Therapeutics Industry Trends
2.3.2 Arginase Deficiency Therapeutics Market Drivers
2.3.3 Arginase Deficiency Therapeutics Market Challenges
2.3.4 Arginase Deficiency Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Arginase Deficiency Therapeutics Players by Revenue
3.1.1 Global Top Arginase Deficiency Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Arginase Deficiency Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Arginase Deficiency Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Arginase Deficiency Therapeutics Revenue
3.4 Global Arginase Deficiency Therapeutics Market Concentration Ratio
3.4.1 Global Arginase Deficiency Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Arginase Deficiency Therapeutics Revenue in 2023
3.5 Arginase Deficiency Therapeutics Key Players Head office and Area Served
3.6 Key Players Arginase Deficiency Therapeutics Product Solution and Service
3.7 Date of Enter into Arginase Deficiency Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Arginase Deficiency Therapeutics Breakdown Data by Type
4.1 Global Arginase Deficiency Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Arginase Deficiency Therapeutics Forecasted Market Size by Type (2025-2030)
5 Arginase Deficiency Therapeutics Breakdown Data by Application
5.1 Global Arginase Deficiency Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Arginase Deficiency Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Arginase Deficiency Therapeutics Market Size (2019-2030)
6.2 North America Arginase Deficiency Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Arginase Deficiency Therapeutics Market Size by Country (2019-2024)
6.4 North America Arginase Deficiency Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Arginase Deficiency Therapeutics Market Size (2019-2030)
7.2 Europe Arginase Deficiency Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Arginase Deficiency Therapeutics Market Size by Country (2019-2024)
7.4 Europe Arginase Deficiency Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Arginase Deficiency Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Arginase Deficiency Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Arginase Deficiency Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Arginase Deficiency Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Arginase Deficiency Therapeutics Market Size (2019-2030)
9.2 Latin America Arginase Deficiency Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Arginase Deficiency Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Arginase Deficiency Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Arginase Deficiency Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Arginase Deficiency Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Arginase Deficiency Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Arginase Deficiency Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Helsinn Healthcare
11.1.1 Helsinn Healthcare Company Detail
11.1.2 Helsinn Healthcare Business Overview
11.1.3 Helsinn Healthcare Arginase Deficiency Therapeutics Introduction
11.1.4 Helsinn Healthcare Revenue in Arginase Deficiency Therapeutics Business (2019-2024)
11.1.5 Helsinn Healthcare Recent Development
11.2 Novartis Pharmaceuticals
11.2.1 Novartis Pharmaceuticals Company Detail
11.2.2 Novartis Pharmaceuticals Business Overview
11.2.3 Novartis Pharmaceuticals Arginase Deficiency Therapeutics Introduction
11.2.4 Novartis Pharmaceuticals Revenue in Arginase Deficiency Therapeutics Business (2019-2024)
11.2.5 Novartis Pharmaceuticals Recent Development
11.3 Horizon Pharma
11.3.1 Horizon Pharma Company Detail
11.3.2 Horizon Pharma Business Overview
11.3.3 Horizon Pharma Arginase Deficiency Therapeutics Introduction
11.3.4 Horizon Pharma Revenue in Arginase Deficiency Therapeutics Business (2019-2024)
11.3.5 Horizon Pharma Recent Development
11.4 Medicis Pharmaceutical
11.4.1 Medicis Pharmaceutical Company Detail
11.4.2 Medicis Pharmaceutical Business Overview
11.4.3 Medicis Pharmaceutical Arginase Deficiency Therapeutics Introduction
11.4.4 Medicis Pharmaceutical Revenue in Arginase Deficiency Therapeutics Business (2019-2024)
11.4.5 Medicis Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
